LIPAC
LIPAC Oncology (LIPAC) is a pharmaceutical company developing innovative and safe chemotherapies that enhance quality of life and survival rates of cancer patients. Our mission is to develop our proprietary delivery platform – LiPaxTM, for the treatment of intracavitary carcinomas such as Bladder, lung and peritoneal or ovarian cancer. LiPax is a precision targeted neoliposomal delivery platform that targets local delivery of paclitaxel for the treatment of multiple carcinomas.
LiPax is in advanced development in Phase 2b for intravesical instillation in the treatment of non-muscle invasive bladder cancer (NMIBC). The neoliposomal platform achieves targeted tissue penetration with no systemic exposure, toxicity or chemo-related side-effects. NMIBC is our most advanced program with additional indications in thoracic cancer (malignant pleural effusion), upper tract urothelial cancer (UTUC), peritoneal and ovarian cancers. For the NMIBC program, LiPax is designed to enhance the standard of care of outpatient endoscopic tumor removal followed by intravesical instillation using a standard urinary catheter. LIPAC Oncology completed a Phase 1-2a clinical trial that demonstrated LiPax was safe and well tolerated and in addition, projected a two-year 83% recurrence free survival (2-YR RFS) rates in patients with low-grade highly recurrent NMIBC treated with LiPax versus 49% RFS for current treatments.
LIPAC is advancing the development of the Liposomal Enhanced IntraThoracic Paclitaxel (LEITP) for the treatment of MPE utilizing the LiPax technology. Preclinical studies with LiPax-PE have demonstrated high potency of LiPax against existing chemotherapy treatment options. Our LiPax-PE program leverages the preclinical studies performed under the NMIBC program. In addition, the low survivability of MPE patients enables a structured clinical end point of improved survival rate and allow for an accelerated approval pathway. LiPax-PE will leverage a potential early approval with a post approval Phase 3 study strategy.